Knowledge and attitudes of patients in primary care on off-label treatment

The International Journal of Risk & Safety in Medicine
Mario Ćurković, Dražen Gorjanski

Abstract

To examine primary care patients' knowledge and attitudes on off-label treatment. In 47 primary care offices in Osijek-Baranja County, 1300 patients were given questionnaires about their knowledge and attitudes on off-label treatment. Questionnaires were completed voluntarily and anonymously. Majority of patients (96.3%) had no knowledge about off-label treatment, and upon having it explained, 42.3% would not accept such treatment under any circumstances, while 54.5% would never accept such treatment for their children. Patients place more trust in primary care doctors than in hospital doctors; 69.6% of patients strongly believe that primary care doctors would not expose them to off-label treatment while only 41.2% of them think the same in relation to hospital doctors. In case of serious consequences following off-label therapy 49.9% of patients would sue doctors who prescribed it. Patients in primary care possess limited knowledge about off-label treatment. Most patients do not wish to be exposed to such treatment, and are particularly reluctant to have their children exposed to it. In case of serious side effects, half of the patients would sue doctors who had prescribed the off-label therapy.

References

Nov 22, 2000·Archives of Disease in Childhood·M ChalumeauG Pons
Feb 28, 2007·British Journal of Clinical Pharmacology·Derek StewartJames S McLay
Jun 7, 2007·Pharmacoepidemiology and Drug Safety·Anita C VolkersLiset van Dijk
Apr 4, 2008·The New England Journal of Medicine·Randall S Stafford
Nov 27, 2008·British Journal of Clinical Pharmacology·T L MukattashJ C McElnay
Mar 12, 2009·European Journal of Pediatrics·Christian LenkClaudia Wiesemann
Jan 19, 2011·European Journal of Clinical Pharmacology·Tareq MukattashJames C McElnay
Jan 22, 2011·Pharmacoepidemiology and Drug Safety·G C AlexanderR S Stafford
Mar 17, 2011·Lancet·Asher Mullard
Aug 19, 2011·European Journal of Clinical Pharmacology·Tareq MukattashJames C McElnay
Aug 19, 2011·American Journal of Law & Medicine·Aaron S Kesselheim
Sep 29, 2011·International Journal of Clinical Pharmacy·Tareq L MukattashJames C McElnay
Mar 28, 2012·CNS Drugs·Andrew McKean, Erik Monasterio
Apr 18, 2012·Archives of Internal Medicine·Tewodros EgualeRobyn Tamblyn
Aug 11, 2012·Mayo Clinic Proceedings·Christopher M WittichWilliam L Lanier
Dec 21, 2012·Expert Review of Anti-infective Therapy·Giannoula S TansarliMatthew E Falagas
Feb 26, 2014·Pediatrics·Daniel A FrattarelliUNKNOWN American Academy of Pediatrics Committee on Drugs
May 7, 2014·Journal of Pharmacology & Pharmacotherapeutics·Sandeep Kumar Gupta, Roopa Prasad Nayak
Jun 7, 2014·The International Journal of Risk & Safety in Medicine·V BangU M Thatte
May 15, 2015·Journal of Pharmacology & Pharmacotherapeutics·Mohd Masnoon SaiyedGaurang Shah
Sep 1, 2015·British Journal of Clinical Pharmacology·S BalanV S L Mak
Jan 13, 2016·The International Journal of Risk & Safety in Medicine·S KannanP P Khosla
Oct 30, 2016·Orphanet Journal of Rare Diseases·Marc DoomsSteven Simoens

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Canadian Medical Association Journal
A A KLASS
Techniques hospitalières, médico-sociales et sanitaires
G DEREVOGE
© 2022 Meta ULC. All rights reserved